SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help tens of millions of people worldwide overcome and prevent difficult-to-treat infections that are also becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp, is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, in late stage development for multiple indications, ranging from vaginal yeast infections to life-threatening fungal infections in hospitalized patients.